FDA Voucher Targets Drug for Rare Syndrome With a Tongue-Twisting Name
Published Date: 10/28/2026
Notice
Summary
The FDA just gave a special priority review voucher to Rare Thyroid Therapeutics International AB for their drug EMCITATE (tiratricol), approved on September 28, 2026. This drug treats a rare childhood disease called Allan-Herndon-Dudley syndrome. This voucher speeds up future FDA reviews, helping the company bring more rare disease treatments to patients faster.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA approves EMCITATE for MCT8 deficiency
The FDA approved EMCITATE (tiratricol) on September 28, 2026. EMCITATE is indicated to treat peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency, also called Allan‑Herndon‑Dudley syndrome.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-21910, Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ATEBRIOZ (Zilurgisertib)
The FDA just gave Incyte Corporation a special priority review voucher for their rare pediatric disease drug, ATEBRIOZ (zilurgisertib), approved on September 25, 2026. This drug helps kids and adults with a rare condition called fibrodysplasia ossificans progressiva (FOP). The voucher speeds up future FDA reviews, saving time and potentially money for Incyte and encouraging more rare disease treatments.
Next: 2026-21912, Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Rapid Response Surveys
The FDA wants your thoughts on using quick surveys to gather safety info faster and make smart decisions about health risks. This affects anyone involved in health and safety data collection and aims to keep things speedy without adding extra paperwork. You’ve got until December 28, 2026, to share your feedback—so don’t miss out!